Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.57 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9440011 | 0.97 | THRA (0.66) | THRATHRBLMNAMAPK1HTT | |
| SCHEMBL15731804 | 0.95 | THRA (0.68) | THRATHRBLMNAMAPK1HTT | |
| SCHEMBL8646009 | 0.95 | THRA (0.68) | THRATHRBLMNAMAPK1HTT | |
| SCHEMBL5347089 | 0.95 | THRA (0.68) | THRATHRBLMNAMAPK1HTT | |
| SCHEMBL9437150 | 0.95 | THRA (0.68) | THRATHRBLMNAMAPK1HTT | |
| SCHEMBL9440284 | 0.95 | THRA (0.68) | THRATHRBLMNAMAPK1HTT | |
| SCHEMBL5358465 | 0.95 | THRA (0.68) | THRATHRBLMNAMAPK1HTT | |
| SCHEMBL9440043 | 0.95 | THRA (0.68) | THRATHRBLMNAMAPK1HTT | |
| Hydrochloric Acid SCHEMBL9626607 | 0.94 | THRA (0.67) | THRATHRBLMNAMAPK1HTT | |
| Hydrochloric Acid SCHEMBL7523098 | 0.94 | THRA (0.67) | THRATHRBLMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| WO-2014133022-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2014-09-04 | — | — | WO | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| CN-1859908-A | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists | MERCK & CO INC (US) | 2006-11-08 | — | — | CN | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | THRA 4014/4885THRB 4348/4885LMNA 2677/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | THRA 4473/4885THRB 3843/4885LMNA 2339/4885 |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | GRM2, GRM1, GRIA2 | THRA 1797/4885THRB 1969/4885LMNA 4725/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | THRA 3985/4885THRB 4200/4885LMNA 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.